Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study

Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Several myths on buprenorphine's pharmacology exist: possible analgesic ceiling effect, feasibility of combination with other opioid agonists, and the reversibility of side effects. Aim to evaluate: 1) if cancer patients receiving high doses of pure agonists could obtain adequate pain relief after switching to transdermal (TD) buprenorphine and 2) whether the numbers of breakthrough pain episodes after switching increased and whether they could be treated with the same doses of pure agonist as before switching.
Original languageEnglish
JournalJournal of Opioid Management
Issue number4
Pages (from-to)255-62
Number of pages8
Publication statusPublished - 2013

ID: 42247757